Outset Medical is a leading medtech innovator delivering first-of-its-kind technology into the growing global dialysis market.
Outset Medical is a pioneering medical technology company reimagining dialysis for patients and providers.
Outset Medical was founded in 2010 and is headquartered in San Jose, California.
Outset Medical is dedicated to technology-driven service model innovation aimed at reducing cost and transforming the patient care experience.
Outset’s Tablo System is FDA-cleared for use in acute and chronic care settings. In addition to its acute and chronic care commercial expansion, the company has concluded a clinical trial to expand Tablo’s labeled indication to include home use.
Outset Medical's human-centered model is designed to dramatically improve not only the care experience – for patients, families, providers and physicians alike – but also cost-efficiencies for providers.
Outset Medical is backed by D1 Capital Partners, T. Rowe Price Associates, Fidelity Management and Research Company, Partner Fund Management, Perceptive Advisors and others. The company raised $125M in a Series E financing on Feb 04, 2020. This brings Outset Medical's total funding to $447.3M to date.